Search results
Showing 6691 to 6705 of 8213 results
This guidance has been updated and replaced by NICE interventional procedures guidance 800.
SIR-Spheres for treating inoperable hepatocellular carcinoma (MIB63)
This medtech innovation briefing has been updated and replaced by NICE technology appraisal guidance 688.
This guidance has been updated and replaced by NICE guideline CG82.
Pneumonia (hospital-acquired): antimicrobial prescribing (NG139)
This guideline has been updated and replaced by NICE's guideline on pneumonia: diagnosis and management (NG250).
Pneumonia (community-acquired): antimicrobial prescribing (NG138)
This guideline has been updated and replaced by NICE's guideline on pneumonia in adults: diagnosis and management (NG250).
This guideline has been updated and replaced by NICE's guideline on pneumonia: diagnosis and management (NG250).
This guidance has been updated and replaced by NICE technology appraisal guidance TA1007.
This guidance has been updated and replaced by NICE technology appraisal guidance 156.
This guidance has been updated and replaced by NICE technology appraisal guidance 898.
Ruxolitinib for treating polycythaemia vera (terminated appraisal) (TA356)
This guidance has been updated and replaced by NICE technology appraisal guidance TA921.
This guidance has been updated and replaced by NICE guideline CG172.
Adalimumab, etanercept and infliximab for ankylosing spondylitis (TA143)
This guidance has been updated and replaced by NICE technology appraisal guidance 383.
Epoetin alfa, epoetin beta and darbepoetin alfa for cancer treatment-induced anaemia (TA142)
This guidance has been replaced by NICE technology appraisal guidance 323.
Obesity in adults: prevention and lifestyle weight management programmes (QS111)
This quality standard has been updated and replaced by NICE quality standard 212.
This quality standard is updated and replaced by the quality standards on type 1 diabetes in adults (QS208) and type 2 diabetes in adults (QS209).